Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture

All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000423
English
Authors' recommendations: Teriparatide (Forsteo®) is not recommended for use within NHS Wales for the treatment of osteoporosis in men at increased risk of fracture.
Details
Project Status: Completed
Year Published: 2008
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Osteoporosis
  • Teriparatide
  • Bone Density Conservation Agents
  • Risk Factors
Contact
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.